Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.


Journal

ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013

Informations de publication

Date de publication:
03 04 2020
Historique:
received: 25 12 2019
pubmed: 1 2 2020
medline: 10 4 2021
entrez: 1 2 2020
Statut: ppublish

Résumé

LSD1 is a lysine demethylase highly involved in initiation and development of cancer. To design highly effective covalent inhibitors, a strategy is to fill its large catalytic cleft by designing tranylcypromine (TCP) analogs decorated with long, hindered substituents. We prepared three series of TCP analogs, carrying aroyl- and arylacetylamino (1 a-h), Z-amino acylamino (2 a-o), or double-substituted benzamide (3 a-n) residues at the C4 or C3 position of the phenyl ring. Further fragments obtained by chemical manipulation applied on the TCP scaffold (compounds 4 a-i) were also prepared. When tested against LSD1, most of 1 and 3 exhibited IC

Identifiants

pubmed: 32003940
doi: 10.1002/cmdc.201900730
pmc: PMC7125024
mid: NIHMS1558148
doi:

Substances chimiques

Antineoplastic Agents 0
Enzyme Inhibitors 0
Tranylcypromine 3E3V44J4Z9
Histone Demethylases EC 1.14.11.-
KDM1A protein, human EC 1.5.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

643-658

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM114306
Pays : United States

Informations de copyright

© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Références

Chem Rev. 2018 Feb 14;118(3):989-1068
pubmed: 28338320
Nature. 2007 Apr 19;446(7138):882-7
pubmed: 17392792
Mol Cell. 2007 Aug 17;27(4):562-72
pubmed: 17707228
Genes Cancer. 2011 Jun;2(6):663-79
pubmed: 21941621
Cancer Cell. 2012 Apr 17;21(4):473-87
pubmed: 22464800
Cancer Res. 2009 Mar 1;69(5):2065-71
pubmed: 19223552
J Am Chem Soc. 2010 May 19;132(19):6827-33
pubmed: 20415477
Eur J Med Chem. 2014 Oct 30;86:352-63
pubmed: 25173853
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9750-5
pubmed: 12913124
J Biol Chem. 2007 Jul 13;282(28):20070-4
pubmed: 17537733
Trends Biochem Sci. 2008 Apr;33(4):181-9
pubmed: 18343668
Cell Rep. 2013 Oct 31;5(2):445-57
pubmed: 24139802
Eur J Med Chem. 2015 Apr 13;94:163-74
pubmed: 25768700
Mol Cancer Ther. 2017 Feb;16(2):273-284
pubmed: 27903753
Int J Cancer. 2016 Jan 15;138(2):428-39
pubmed: 26240060
Leukemia. 2017 Nov;31(11):2303-2314
pubmed: 28210006
J Med Chem. 2016 Feb 25;59(4):1501-17
pubmed: 26702542
Neuro Oncol. 2015 Nov;17(11):1463-73
pubmed: 25795306
Leukemia. 2010 Nov;24(11):1834-43
pubmed: 20861919
ACS Med Chem Lett. 2014 Dec 08;6(2):173-7
pubmed: 25699146
Med Res Rev. 2015 May;35(3):586-618
pubmed: 25418875
J Med Chem. 2009 Apr 9;52(7):1885-902
pubmed: 19284718
Biochem Pharmacol. 1994 Apr 29;47(9):1469-79
pubmed: 8185657
Nat Med. 2012 Mar 11;18(4):605-11
pubmed: 22406747
Oncogene. 2017 Apr 27;36(17):2423-2434
pubmed: 27893719
Nature. 2005 Sep 15;437(7057):432-5
pubmed: 16079794
Cancer Cell. 2018 Mar 12;33(3):495-511.e12
pubmed: 29502954
Blood. 2014 Jul 3;124(1):151-2
pubmed: 24993879
Cancer Res. 2011 Dec 1;71(23):7238-49
pubmed: 21975933
Carcinogenesis. 2010 Mar;31(3):512-20
pubmed: 20042638
Nat Cell Biol. 2007 Mar;9(3):347-53
pubmed: 17277772
Epigenomics. 2016 Aug;8(8):1103-16
pubmed: 27479862
Nature. 2013 Oct 24;502(7472):480-8
pubmed: 24153301
J Am Chem Soc. 2015 Feb 11;137(5):2042-6
pubmed: 25581489
J Am Chem Soc. 2017 Aug 23;139(33):11357-11360
pubmed: 28809490
Oncotarget. 2017 Jun 19;8(49):85085-85101
pubmed: 29156705
Cancer Res. 2016 Apr 1;76(7):1975-88
pubmed: 26837761

Auteurs

Rossella Fioravanti (R)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185, Rome, Italy.

Annalisa Romanelli (A)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185, Rome, Italy.

Nicola Mautone (N)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185, Rome, Italy.

Elisabetta Di Bello (E)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185, Rome, Italy.

Annarita Rovere (A)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185, Rome, Italy.

Davide Corinti (D)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185, Rome, Italy.

Clemens Zwergel (C)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185, Rome, Italy.
Department of Medicine of Precision, University of Studi della Campania Luigi Vanvitelli, Vico L. De Crecchio 7, 80138, Naples, Italy.

Sergio Valente (S)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185, Rome, Italy.

Dante Rotili (D)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185, Rome, Italy.

Oronza A Botrugno (OA)

Department of Experimental Oncology, IEO - European Institute of Oncology IRCCS, via Adamello 16, 20139, Milan, Italy.
IRCCS San Raffaele Scientific Institute, Via Olgettina Milano, 58, 20132, Milan, Italy.

Paola Dessanti (P)

Department of Experimental Oncology, IEO - European Institute of Oncology IRCCS, via Adamello 16, 20139, Milan, Italy.
Oryzon Genomics S.A., Sant Ferran, 08940 Cornellà de Llobregat, Barcelona, Spain.

Stefania Vultaggio (S)

Department of Experimental Oncology, IEO - European Institute of Oncology IRCCS, via Adamello 16, 20139, Milan, Italy.

Paola Vianello (P)

Department of Experimental Oncology, IEO - European Institute of Oncology IRCCS, via Adamello 16, 20139, Milan, Italy.

Anna Cappa (A)

Department of Experimental Oncology, IEO - European Institute of Oncology IRCCS, via Adamello 16, 20139, Milan, Italy.
Experimental Therapeutics Program, IFOM-FIRC Institute of Molecular Oncology Foundation, via Adamello 16, 20139, Milan, Italy.

Claudia Binda (C)

Department of Biology and Biotechnology, University of Pavia, Via Ferrata 9, 27100, Pavia, Italy.

Andrea Mattevi (A)

Department of Biology and Biotechnology, University of Pavia, Via Ferrata 9, 27100, Pavia, Italy.

Saverio Minucci (S)

Department of Experimental Oncology, IEO - European Institute of Oncology IRCCS, via Adamello 16, 20139, Milan, Italy.
Department of Biosciences, University of Milan, Via Festa del Perdono 7, 20122, Milano, Italy.

Ciro Mercurio (C)

Department of Experimental Oncology, IEO - European Institute of Oncology IRCCS, via Adamello 16, 20139, Milan, Italy.
Experimental Therapeutics Program, IFOM-FIRC Institute of Molecular Oncology Foundation, via Adamello 16, 20139, Milan, Italy.

Mario Varasi (M)

Department of Experimental Oncology, IEO - European Institute of Oncology IRCCS, via Adamello 16, 20139, Milan, Italy.
Experimental Therapeutics Program, IFOM-FIRC Institute of Molecular Oncology Foundation, via Adamello 16, 20139, Milan, Italy.

Antonello Mai (A)

Department of Drug Chemistry and Technologies, Sapienza University of Rome, P. le A. Moro 5, 00185, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH